HER2基因表达水平在CALGB/SWOG 80405试验入组的转移性结直肠癌患者中具有预测和预后价值
CALGB/SWOG 80405 III期试验中,559例患者通过NGS检测HER2扩增,925例通过NanoString检测基因表达。高HER2表达与较长无进展生存期和总生存期相关;在低HER2表达组,西妥昔单抗相比贝伐珠单抗的无进展生存期和总生存期更差,HER2表达与治疗组存在显著交互作用。
要点
- 高HER2表达(按中位数二分)与较长无进展生存期(11.6 vs 10个月,P=.012)和总生存期(32 vs 25.3个月,P=.033)相关,独立于治疗。
- 高HER2表达组中西妥昔单抗相比贝伐珠单抗有总生存获益(P=.02),低表达组中西妥昔单抗无进展生存期更差(P=.019)。
- HER2表达低于中位数的患者,西妥昔单抗相比贝伐珠单抗的无进展生存期(HR 1.38,95%CI 1.12-1.71,校正P=.0027)和总生存期(HR 1.28,95%CI 1.02-1.59,校正P=.03)更差。
核心结论
- HER2基因表达在CALGB/SWOG 80405试验中具有预后和预测价值。
- 肿瘤HER2表达可能有助于治疗选择,低HER2表达患者 favoring 贝伐珠单抗而非西妥昔单抗为基础的治疗。
研究设计与样本
- III期CALGB/SWOG 80405试验,转移性结直肠癌患者一线化疗联合贝伐珠单抗或西妥昔单抗。
- 559例患者原发肿瘤DNA通过NGS(FoundationOne CDx)检测HER2扩增。
- 925例患者肿瘤组织通过NanoString 800基因面板检测基因表达。
- 终点为总生存期和无进展生存期。
主要发现
- 高HER2表达(按中位数二分)与较长无进展生存期(11.6 vs 10个月,P=.012)和总生存期(32 vs 25.3个月,P=.033)相关,独立于治疗。
- 高HER2表达组中西妥昔单抗相比贝伐珠单抗有总生存获益(P=.02),低表达组中西妥昔单抗无进展生存期更差(P=.019)。
- HER2表达作为连续变量,增加与较长总生存期(HR 0.83,95%CI 0.75-0.93,校正P=.0007)和无进展生存期(HR 0.82,95%CI 0.74-0.91,校正P=.0002)相关,在中位数后达到平台效应。
- HER2表达低于中位数的患者,西妥昔单抗相比贝伐珠单抗的无进展生存期(HR 1.38,95%CI 1.12-1.71,校正P=.0027)和总生存期(HR 1.28,95%CI 1.02-1.59,校正P=.03)更差。
- HER2表达与治疗组间对总生存期(交互P=.017)、无进展生存期(交互P=.048)和客观缓解率(交互P=.001)存在显著交互作用。
临床怎么用
- HER2肿瘤表达可能有助于低HER2表达患者的治疗选择, favoring 贝伐珠单抗而非西妥昔单抗为基础的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of HER2 amplification and gene expression using next-generation sequencing (NGS) and NanoString data. PATIENTS AND METHODS: Primary tumor DNA from 559 patients was profiled for HER2 amplification by NGS (FoundationOne CDx). Tumor tissue from 925 patients was tested for NanoString gene expression using an 800-gene panel. OS and progression-free survival (PFS) were the time-to-event end points. RESULTS: High HER2 expression (dichotomized at median) was associated with longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment. An OS benefit for cetuximab versus bevacizumab was observed in the high HER2 expression group (P = .02), whereas a worse PFS for cetuximab was seen in the low-expression group (P = .019). When modeled as a continuous variable, increased HER2 expression was associated with longer OS (hazard ratio [HR], 0.83 [95% CI, 0.75 to 0.93]; adjusted P = .0007) and PFS (HR, 0.82 [95% CI, 0.74 to 0.91]; adjusted P = .0002), reaching a plateau effect after the median. In patients with HER2 expression lower than median, treatment with cetuximab was associated with worse PFS (HR, 1.38 [95% CI, 1.12 to 1.71]; adjusted P = .0027) and OS (HR, 1.28 [95% CI, 1.02 to 1.59]; adjusted P = .03) compared with that with bevacizumab. A significant interaction between HER2 expression and the treatment arm was observed for OS (Pintx = .017), PFS (Pintx = .048), and objective response rate (Pintx = .001). CONCLUSION: HER2 gene expression was prognostic and predictive in CALGB/SWOG 80405. HER2 tumor expression may inform treatment selection for patients with low HER2 favoring bevacizumab- versus cetuximab-based therapies.
引用
- Battaglin F, Ou FS, Qu X, et al. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. J Clin Oncol. 2024. PMID: 38457761. doi:10.1200/JCO.23.01507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。